Diabetes care improves when support adapts to real-life changes, removing barriers and sustaining daily habits beyond reminders, education, and one-time interventions. Imagine a woman who picks up her ...

Regulatory clearance includes Guardant360 CDx to select patients with ESR1 mutations for imlunestrant plus abemaciclib in ER+/HER2– advanced disease after endocrine-therapy progression. Phase 3 ...

What the Data Show," Dr. Vaduganathan walks through the cardiovascular outcomes trials that built the evidence base for SGLT2 i ...

The global prevalence rate of infertility linked to endometriosis fell by nearly 30% between 1990 and 2021, yet the total number of affected women climbed by 9.1% over the same period, according to an ...

Three machine learning models trained to predict recurrent autoimmune hepatitis after liver transplantation were all outperformed by ordinary logistic regression, which reached an ...

This year’s World Alzheimer’s Day theme is “The Earlier You Know, The More You Can Do: A Dementia Diagnosis Matters,” observed September 21, 2026, bringing attention to the disease and the importance ...

In the phase 4 IMMpactful trial, 57.3% of biologic-naive adults with moderate psoriasis reached PASI 90 on risankizumab at week 16 against 22.9% on deucravacitinib, a gap of more than 34 percentage ...

The FDA approved rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx), also known as UX111, last week, on September 17, making it the first FDA-approved treatment for pediatric patients with ...

Seven attributes significantly influenced choices; importance ranked itch (22%) and appearance (21%) above cancer (16%), infection (14%), pain (13%), administration (7%), and major heart problems (6%) ...

Led by the moderator, the expert neurology and primary care panelists examined what an ideal training curriculum looks like.

In "Where MAC and NTM Research Is Headed Next," our expert turns to the research priorities that could reshape MAC and NTM ...

In "New ASCO Data on CAR T-Cell Therapy Outcomes by Site Type," Dr. Porter reviews new ASCO data alongside his own center's ...